TERAZOL 3
LOE ApproachingNDAVAGINALSUPPOSITORY
Approved
May 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TERAZOL 3 is a vaginal antifungal suppository approved in 1988 for the treatment of vaginal yeast infections (vulvovaginal candidiasis). The drug contains terconazole, an imidazole antifungal agent that disrupts fungal cell membrane synthesis. It is a non-systemic, localized treatment administered directly to the vaginal site.
LOE Approaching
As LOE approaches, the brand team is likely contracting; roles are shifting toward generic transition planning and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TERAZOL 3 offers limited growth and stability challenges due to its LOE-approaching lifecycle stage. Careers on this product are best suited for professionals focused on operational efficiency, cost management, and transition planning rather than commercial expansion.
Brand ManagerProduct Manager
Worked on TERAZOL 3 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.